Dr. Caroline Okorie is a Clinical Assistant Professor of Pediatrics at the Stanford University School of Medicine. She completed her residency and chief residency in pediatrics at Oregon Health & Science University in Portland, Oregon and her fellowship in pediatric pulmonology here at Lucile Packard Children’s Hospital Stanford. She also completed a fellowship in sleep medicine at the Stanford Sleep Medicine Center.
- Pediatric Pulmonary
- Sleep Medicine
- Neuromuscular Disease
Clinical Assistant Professor, Pediatrics - Pulmonary Medicine
Associate Program Director, Stanford Pediatrics Residency Program, Stanford School of Medicine, Department of Pediatrics (2019 - Present)
Faculty Coach, Stanford Pediatrics Residency Program, Stanford School of Medicine, Department of Pediatrics (2018 - Present)
Boards, Advisory Committees, Professional Organizations
Member, American Thoracic Society Education Committee (2019 - Present)
Board Certification, American Board of Pediatrics, Pediatric Pulmonary Medicine (2018)
Board Certification, American Board of Pediatrics, Pediatrics (2013)
Fellowship, Stanford University, Department of Psychiatry, Sleep Medicine (2018)
Fellowship, Stanford University, Department of Pediatrics, Pediatric Pulmonary Medicine (2017)
Chief Residency, Oregon Health & Science University, Pediatrics (2014)
Residency, Oregon Health & Science University, Pediatrics (2013)
MD, University of Arizona College of Medicine, Medicine (2010)
MPH, Mel and Enid Zuckerman College of Public Health, Public Health (2010)
BA, Stanford University, English Literature (2003)
- Sleep The Handbook of Personal Health and Wellbeing for Physicians and Trainees edited by Weiss Roberts, L., Trockel, M. Springer International Publishing. 2019
The nocturnal-polysomnogram and "non-hypoxic sleep-disordered-breathing" in children.
OBJECTIVE: To characterize sleep-disordered breathing patterns not related to hypoxia resulting in fragmented sleep in children.METHODS: We reviewed the polysomnogram (PSG) data of children with sleep complaints who were being evaluated for sleep-disordered breathing and had an apnea-hypopnea-index≤3. These data were compared to the recordings of the same children with nasal CPAP administered for one night and to 60 control subjects (children without any sleep complaints). A subgroup of children was monitored with esophageal manometry, but nasal cannula flow data was recorded in all cases.RESULTS: Abnormal breathing patterns, particularly flow limitation, could be seen with more severity and frequency compared to apnea or hypopnea. The observed abnormal breathing patterns were associated with EEG disturbances.CONCLUSIONS: Patterns such as flow-limitation, mouth-breathing, changes in inspiratory and expiratory time, rib-cage and expiratory muscle activity, transcutaneous CO2 electrode changes and snoring noises are all variables that should be systematically reviewed when analyzing nocturnal PSG. Current scoring guidelines emphasizes apnea-hypopnea and hypoxic-sleep disordered breathing and therefore treatment is often much delayed in this population of children with evidence of abnormal breathing patterns. Analysis of the various patterns of abnormal breathing noted above allows recognition of "non-hypoxic" sleep-disordered-breathing (SDB).
View details for PubMedID 30578113
Diagnosis And Management Of Sporadic Pulmonary Arteriovenous Malformation Not Associated With Hereditary Hemorrhagic Telangiectasia
AMER THORACIC SOC. 2016
View details for Web of Science ID 000390749605287
Allergic Bronchopulmonary Aspergillosis
Journal of Fungi
2016; 2 (2): 17
View details for DOI 10.3390/jof2020017
Allergic Bronchopulmonary Aspergillosis.
Journal of fungi (Basel, Switzerland)
2016; 2 (2)
Allergic bronchopulmonary aspergillosis (ABPA), a progressive fungal allergic lung disease, is a common complication of asthma or cystic fibrosis. Although ABPA has been recognized since the 1950s, recent research has underscored the importance of Th2 immune deviation and granulocyte activation in its pathogenesis. There is also strong evidence of widespread under-diagnosis due to the complexity and lack of standardization of diagnostic criteria. Treatment has long focused on downregulation of the inflammatory response with prolonged courses of oral glucocorticosteroids, but more recently concerns with steroid toxicity and availability of new treatment modalities has led to trials of oral azoles, inhaled amphotericin, pulse intravenous steroids, and subcutaneously-injected anti-IgE monoclonal antibody omalizumab, all of which show evidence of efficacy and reduced toxicity.
View details for PubMedID 29376934
A Presentation Of Hepatopulmonary Syndrome In A Five Year Old During Evaluation For Miliary Tuberculosis
AMER THORACIC SOC. 2015
View details for Web of Science ID 000377582808172
Successful Treatment Of Mineral Oil Associated Lipoid Pneumonia In An Infant
AMER THORACIC SOC. 2013
View details for Web of Science ID 000209839101412